Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.
Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.
CAR T-cell therapies have been making their way through the field of multiple myeloma. Studies presented at the 2017 ASCO Annual Meeting showed that when targeting BCMA, CAR T-cell technology appeared to be tolerable and efficacious, Usmani says.
Larger cohorts are needed though, Usmani adds, as investigators still must indicate which patients will benefit from this therapy.
